ABSTRACT
This chapter attempts to go some way in defending the view that a commercial model ought to be the default model for plasma collections used to make plasma derived therapies. The commercial model has a record of generating plasma collection surpluses, while non-commercial models operate at plasma collection deficits. The commercial model therefore better preserves and promotes security of supply of therapies and so patient health, while non-commercial models put patient health at risk. The challenge to those who think banning commercial models is a good idea is to offer reasons that are important enough to justify the foreseeable risk to patient health. This chapter argues that the challenge has not been met. One set of arguments typically offered in support of payment prohibitions appeal to donor altruism and community solidarity, and another set appeal to a variety of possible harms to donors, including donor health, donor dignity, and wrongful exploitation. This chapter explores each of these arguments but finds them inadequate and concludes that bans on commercial models put patient health at risk without promoting, preserving, or protecting anything of comparable moral weight.
